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Andréa Dâmaso Bertoldi1,2*, Ana Paula Helfer3, Aline L Camargo4, Noêmia U L Tavares5 and Panos Kanavos2Abstract
Background: To evaluate medicine prices, availability and affordability in Brazil, considering the differences across
three types of medicines (originator brands, generics and similar medicines) and different types of facilities (private
pharmacies, public sector pharmacies and “popular pharmacies”).
Methods: Data on prices and availability of 50 medicines were collected in 56 pharmacies across six cities in
Southern Brazil using the World Health Organization / Health Action International methodology. Median prices
obtained were divided by international reference prices to derive the median price ratio (MPR).
Results: In the private sector, prices were 8.6 MPR for similar medicines, 11.3 MRP for generics and 18.7 MRP for
originator brands, respectively. Mean availability was 65%, 74% and 48% for originator brands, generics and similar
medicines, respectively. In the public sector, mean availability of similar medicines was 2–7 times higher than that
of generics. Mean overall availability in the public sector ranged from 68.8% to 81.7%. In “popular pharmacies”,
mean availability was greater than 90% in all cities.
Conclusions: Availability of medicines in the public sector does not meet the challenge of supplying essential
medicines to the entire population, as stated in the Brazilian constitution. This has unavoidable repercussions for
affordability, particularly amongst the lower socio-economic strata.
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The Brazilian Universal Health System (SUS) is commit-
ted to offer high-quality health care to the entire popula-
tion, including the distribution free of charge of a list of
essential medicines aimed at treating the most prevalent
diseases in the population. Also, the government pro-
vides expensive medicines for treating rare diseases or
medicines targeting small groups (e.g. Crohn’s disease,
hepatitis B and C) free of charge, based on clinical pro-
tocols and therapeutic guidelines from the Ministry of
Health [1]. Charging patients for medicines is strictly
prohibited in the public system. In real life, however,
medicines are often not available when needed. Studies
carried out in Brazil have shown that, on average, 40% of
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reproduction in any medium, provided the orwere not available when needed [2,3]. Although access
to medicines in Brazil is high [4,5], socioeconomic in-
equities are observed [4]. Despite poor families receiving
more medicines free of charge from government-funded
sources than the better-off, 25.5% of the medicines
obtained by the bottom income quintile of the popula-
tion are paid for out-of-pocket [4].
Overall, Brazilian families spend 9% of their household
income on health, and medicines account for the largest
proportion of all health expenses [6]; 31.5% of monthly
health expenses and 2% of monthly family income were
shown to be spent on medicines[7]. Although the major-
ity of the Brazilian population uses SUS, 25% of all fam-
ilies pay for private health insurance [8], which in Brazil
does not cover the costs of medicines used in ambula-
tory care. In 2007, Brazilian families spent 10 times more
money on medicines than the government [9].
In order to compensate for the limitations in the avail-
ability of free medicines in the public sector, the
Brazilian government launched the “popular pharmacy”Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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low prices to the population, particularly those who use
private health facilities but who have difficulty in buying
their medicines in private pharmacies [10]. There are
two types of “popular pharmacies”: (a) those which are
run by the state, city governments, universities or other
health-related institutions. In these pharmacies, medi-
cines from a list comprising 95 molecules selected on
the basis of the most prevalent health problems in Brazil
or which are expensive for individuals to acquire are
sold at cost prices. From here onwards we refer to these
facilities as exclusive “popular pharmacies”; (b) those
which are run in partnership with private pharmacies
using a system of co-payments. This category was created
in 2006 as a means to expand the popular pharmacy pro-
gram. In these facilities the government covers 90% of the
price whereas the patient pays the remaining 10%. How-
ever, only a list of anti-hypertensive, anti-diabetic and
contraceptive medicines are sold in this way [10].
There are three types of medicines available in the
Brazilian market: originator brands, generics and similar
medicines [11]. All generic medicines must be commer-
cialized with no brand. Generics are medicines which
are interchangeable with the originator brand (subject to
the standard bioequivalence and bioavailability tests)
[12]. Bioequivalence is a term in pharmacokinetics used
to assess the expected in vivo biological equivalence of
two proprietary preparations of a drug. If two products
are said to be bioequivalent it means that they would be
expected to be, for all intents and purposes, the same.
Birkett (2003) defined bioequivalence by stating that,
"two pharmaceutical products are bioequivalent if they
are pharmaceutically equivalent and their bioavailabil-
ities (rate and extent of availability) after administration
in the same molar dose are similar to such a degree that
their effects, with respect to both efficacy and safety, can
be expected to be essentially the same. Pharmaceutical
equivalence implies the same amount of the same active
substance(s), in the same dosage form, for the same route
of administration and meeting the same or comparable
standards”[13].
Similar medicines are all the others available on the
market. This type of medicine is comparable to “branded
generics” [14] described in the international literature.
Branded generics are generics whose manufacturers
launch them with a particular brand name, which can be
a ‘fantasy’ or invented name (protected by trademark
law), or the name of the manufacturer followed by the
name of the molecule [14]. Until recently, similar
medicines were required to undergo pharmaceutical
equivalence, but not bioavailability tests, making them
frequently cheaper than generics. However, there is atransition period expiring at the end of 2014 enabling
them to be on the market without these tests [15].
Medicine access relates both to affordability and avail-
ability (available stock of essential medicines in pharma-
cies). Availability, particularly in the public sector, is an
issue of considerable concern in Brazil. Recent research
found that for 71% of medicines the availability of gener-
ics was below 10% [16]. International evidence, using
data from 36 low and middle-income countries, showed
that in the public sector, availability ranged from 29 to
54% and prices for private patients were 9 to 25 times
higher than international reference prices for generics
and 20 times higher for originator products [17].
Retail prices are the result of a series of factors, such
as procurement prices. In the private sector, the volume
of purchases in the pharmacies is usually low, resulting
in purchases from wholesalers, increasing the price for
consumers [18]. There is an exception related to the big
chains of pharmacies, which can centralize the procure-
ment process decreasing significantly the medicine costs,
usually transferring it to the final consumer. The
Brazilian retail market is formed mainly by independent
pharmacies (around 90% of the pharmacies). The five
main chains of pharmacies represent only 2.8% of the
total number of pharmacies in the country, although
they were responsible for 23% of the market share of
medicines in 2010 [19].
In the public sector, a series of different procurement
models is used by governments from developing coun-
tries to purchase medicines and other health products.
An increasing number of countries have opted to
decentralize the procurement process as an effort to an-
swer to local needs. The decentralized purchase involves
different levels of responsibility in the procurement
process at the federal, state and city levels [20].
In Brazil, the procurement of medicines in the public
sector is decentralized at different government levels. All
purchases are carried out by invitation, following a
Federal Law [21], and usually are made directly from the
manufacturers. Considering the heterogeneity of the
Brazilian municipalities, regarding size as well as
organization, there are relevant differences in the pro-
curement prices of medicines [22]. However, many
Brazilian municipalities are already organized to pur-
chase in large scale, which may lead to better prices [23].
Taking into account that both the availability of medi-
cines, particularly in the public sector, and their price in
the private sector are important determinants of access
to medicines, this study aims to investigate medicine
prices, availability and affordability in the Brazilian state
of Rio Grande do Sul, located in the South of the
country. Particular attention is given to the three types
of medicines available in Brazil, notably originator
brands, generics and similar medicines and the different
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macies and “popular pharmacies”).
Methods
The paper uses the World Health Organization / Health
Action International (WHO/HAI) methodology [24] to
study price levels, availability and affordability of medi-
cines in the Southern Region of Brazil. This method-
ology enables researchers to investigate the (a) prices
people pay for key medicinesa; (b) variability of prices
and availability of medicines in different market seg-
ments (public, private and other medicine outlets); (c)
differences in prices and availability between originator
brands and generics; and (d) affordability of medicines
among “ordinary”b people [24].
The methodology relies on conducting surveys, whose
key design elements are: (a) data collection takes place
in six areas of a selected country or state (in the case of
large countries, like Brazil); (b) the survey includes phar-
macy outlets from both the public and private sectors;
(c) up to 50 medicines are surveyed; (d) data on prices
and availability of medicines are obtained by data collec-
tors during visits to the selected pharmacy outlets; (e)
for each medicine and pharmacy outlet, data are col-
lected on the originator brand and the lowest-priced
generic.
The current study has drawn data from the southern
region of Brazil (“South”), which is one of five geograph-
ical regions of the country (South, Southeast, Midwest,
Northeast and North). The South Region consists of
three states (Parana, Santa Catarina and Rio Grande do
Sul). The sample used in this study was drawn from the
state of Rio Grande do Sul, which has a total population
of 10.5 million, representing 5.7% of the country’s total
population [25].
Data were collected from six cities within the state: (a)
the state capital (Porto Alegre, 1.4 million inhabitants); (b)
two cities in the Southern part of the state (Pelotas and
Bagé), which are the poorest in the state; (c) one city in
the metropolitan area of the state capital (São Leopoldo);
(d) one city in the richest part of the state (Caxias do Sul);
and (e) one city in the central region of the state (Santa
Cruz do Sul). The total population of these six cities
represents one quarter of the state’s total population.
The state of Rio Grande do Sul ranks 6th in the
country (out of 26 states) in terms of gross domestic
product (GDP), with a GDP per capita above the na-
tional average of R$13,720 (US$5,900) per capita. Pov-
erty and income inequality are below the national
average [26]. GDP varies considerably across the six
study cities, with three having a GDP per capita below
the national and state average (São Leopoldo, Pelotas
and Bagé) while the remaining three (Porto Alegre,
Santa Cruz do Sul e Caxias do Sul) are above theseaverages [26]. The proportion of individuals below the
poverty threshold was under 30% in all cities (below the
national average of 36.5%) [25].
The sampling for the survey reflected all ambulatory
types of pharmacy outlets. In each of the six cities, four
public sector facilities with pharmacies were randomly
selected from a list of all public sector facilities that dis-
pense medicines in each city. The only exception was
São Leopoldo, where only two health facilities dispensed
medicines (n = 22). Five private pharmacies per city were
also selected and were matched to the public sector fa-
cilities based on their proximity to them (n = 30). In
addition, all exclusive “popular pharmacies” (n = 4) were
included in the study. The total sample size was N= 56.
Pharmacies were visited only once, and interviewers
requested to see the packaging of all medicines surveyed.
All pharmacies agreed to take part in the study and a
written informed consent form was signed prior to data
collection.
Data were collected from the beginning of November
2008 to the end of January 2009. Prices and availability
of 50 medicines were investigated. Of these, 29 medi-
cines were part of the WHO/HAI global and regional
core lists, whereas the remainder, the supplementary list,
were selected from the national (RENAME) and munici-
pal (REMUME) lists of essential medicines [27]. Medi-
cines from the global core list are to be included in all
medicine price surveys, in order to enable international
comparisons. The regional core list is study-specific and
accounts for regional differences in medicine usage, but
still allows for cross-country comparisons within the
same broad geographical region. The supplementary list
of 21 medicines is selected at the country level consider-
ing local particularities. The REMUME is part of the
RENAME list, following the local epidemiological profile
and is obtained directly from the health secretariats of
each city. The 50 medicines selected correspond to
12.6% of the 342 medicines that were part of the na-
tional essential list (RENAME) in 2008. The names of all
medicines included in each list (global, regional and
supplementary list) are presented in Additional file 1:
Table S1.
Antidepressants, anti-epileptics and anxiolytics are
subject to controlled dispensing and are distributed by a
restricted number of pharmacies. Due care was exercised
to include as many of these pharmacies in the sample as
possible. For each selected medicine, data for the follow-
ing variables were obtained: availability at each sampled
outlet, patient price for the originator brand, the lowest-
priced generic and the lowest-priced similar medicine.
The study endpoints comprised three measures: avail-
ability, medicine prices and affordability. Availability was
defined as the proportion of pharmacies in which the
medicines were available at the time of the survey. The
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age percentage value from all medicines. Prices were
presented as median price ratios (MPR). The MPR is the
ratio of a medicine’s median price across outlets divided
by the Management Science for Health (MSH) median
international reference price for the year preceding the
survey (2007) [28]. This study specifically looks at retail
prices in both private and exclusive “popular pharma-
cies”. Prices collected in the public sector were procure-
ment prices and they were not analyzed.
Affordability was estimated as the number of days that
the lowest-paid unskilled government worker earning
the minimum monthly wage would need to work in
order to purchase a complete course of treatment in a
private pharmacy. The gross minimum monthly wage in
Brazil in the end of 2008 was R$415 (US$178.50); after
excluding 8% for national insurance contributions, the
adjusted value was R$381.80 (US$165) [29].
Data entry and analyses were performed using the
computerized ExcelR WHO/HAI Medicine Pricing
Workbook, enhanced for the purpose of including ori-
ginator brands, generics and similar medicines, thus tak-
ing into account the peculiarities of the Brazilian
contextc.
MPRs in private pharmacies were only calculated if
the medicine was available on, at least, four facilities. In
the case of “popular pharmacies”, due to the small sam-
ple size, calculations of MPR were performed if the
medicine was available in at least one facility. Median
price differences across the three types of medicines
included only medicines for which the pair was found in
at least one facility.
In order to estimate the mean availability of medicines
in the exclusive “popular pharmacies”, only 36 medicines
were included in this part of the analysis, as the
remaining 14 were not commercially available in this
type of facility. To avoid underestimation of availability
of generic medicines, all cases in which generics were
not available in the Brazilian market were excluded from
the calculations of availability.
The project was approved by the Ethics Committee
from the Municipal Secretariat of Porto Alegre. People
responsible for providing information on each pharmacy
provided written informed consent.
Results
Additional file 1: Table S1. describes all medicines stud-
ied in terms of pharmacological groups, their presence
or not in the Brazilian list of essential medicines
(RENAME) and availability of the three types of medi-
cines in the public and private sectors. Out of the 50
medicines studied, 43 are part of RENAME. The follow-
ing medicines, which come either from the global orfrom the regional list, are neither part of RENAME nor
REMUME: atorvastatin 10 mg tab, clotrimazole 10 mg/g
cr, ibuprofen 400 mg cap and simvastatin 20 mg tab.
Table 1 shows the mean proportion of availability in
the public sector. As expected, no originator brands
were found in public sector facilities. Mean availability
of similar medicines was 2–7 times greater than that of
generics; this difference was larger in the poorest cities
(São Leopoldo, Pelotas and Bagé) compared to the
wealthier ones. Availability, independently of the type of
medicine (generic or similar), was 78.3% in Porto Alegre,
71.5% in Santa Cruz, 77.0% in Caxias do Sul, 80.3% in
São Leopoldo, 68.8% in Pelotas and 81.7% in Bagé.
Mean availability of lowest-priced generics was lowest
in “popular pharmacies” of the two poorest cities (São
Leopoldo e Bagé) and availability of lowest-priced similar
medicines was lower in the two wealthier ones (Porto
Alegre e Caxias do Sul) (Table 2). No originator brands
were found in “popular pharmacies”. Mean availability,
independently of the type of medicine (generic or simi-
lar), was greater than 90% in all cities: 91.6% in Porto
Alegre, 91.6% in Caxias do Sul, 97.2% in São Leopoldo
and 97.3% in Bagé. In relation to prices, the values were
very similar for the lowest-priced similar medicines, but
ranged from 2.6 to 4.1 MPR for the lowest-priced
generics.
Table 3 presents data on the availability of medicines
and prices in the private sector. Mean availability of ori-
ginator brands ranged from 48 to 91%; equivalent figures
were 63 to 88% for lowest-priced generics and 39 to 55%
for lowest-priced similar medicines. The availability of
originator brands was higher in the two poorest cities
(Pelotas and Bagé). Overall, mean availability was 65%,
74% and 48% for originator brands, generics and similar
medicines, respectively. In terms of MPR, values ranged
from 8.6 for lowest-priced similar medicines to 18.7 for
originator brands; MPR was 11.3 for lowest-priced
generics.
Taking into account all cities together, the price of
both generics and similar medicines is roughly half the
price of originator brands (Figure 1). The greatest differ-
ence between similar medicines and originator brands
was found in Bagé (similar medicines were 62% cheaper
than originator brands) whereas the smallest difference
was found in São Leopoldo (generics were 40% cheaper
than originator brands).
The price difference recorded between originator
brand and generics or similar medicines have significant
implications for affordability (Figure 2). A seven-day
treatment with originator brand ciprofloxacin 500 mg
would cost 13.7 days of salary; the equivalent figures
were 2.2 and 1.9 days for similar and generic medicines.
For a seven-day treatment with amoxicillin 500 mg, the
values are 3.4 (originator brand) and 1.1 and 1.2 days
Table 1 Mean availability (%) of medicines1 in the public





Mean %2 SD %3 Mean % SD %
Porto Alegre 30 23.3 41.9 55.8 41.9
Santa Cruz do Sul 38 14.5 31.6 59.9 39.7
Caxias do Sul 35 17.1 32.5 62,9 39.5
São Leopoldo 33 13.6 31.3 69.7 43.2
Pelotas 32 8.9 21.0 61.7 39.6
Bagé 26 11.5 27.6 70.2 38.1
1Only medicines included in the list of essential medicines within each city
were included in this analysis.
2Mean avalability %3Standard deviation %.
Sample of six cities from the Rio Grande do Sul state, Brazil, 2008-9.
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treatment with glibenclamide 5 mg, the differences were
very small (values around 1.0 day for similar and generic
medicines and 1.5 for originator brand). A 30-day ulcer
treatment with ranitidine 150 mg would cost 9.2 (origi-
nator brand) and 3.3 and 3.0 days (generics and similar
medicines respectively). The originator medicine for a
30-day treatment for asthma (salbutamol inhaler, 200
doses) would cost 2.1 (originator brand) and 1.6 days
(similar medicine). No generics are available for salbuta-
mol inhaler in the Brazilian market.
Discussion
Our results suggest, first, that prices of generics and similar
medicines are, on average, half those of originator brands.
The MPR for all medicines (brands, generics and similars)
was found in all cases to be significantly greater than one,
indicating that prices in Brazil are higher than international
reference prices. Public sector availability of generics or
similar medicines is lower than expected and, consequently,
patients resort more often to purchasing medicines in pri-
vate pharmacies, where availability is higher, but prices are
high and patients have to pay fully out-of-pocket, thus
impacting affordability.Table 2 Mean availability (%) and price of the 36 medicines d
City Lowest-priced generic
n1 Price Availab
MPR2 (Min—Max) Mean %
Porto Alegre 8 3.63 (1.30–11.41) 22.2 (42.
Caxias do Sul 8 2.88 (1.30–11.41) 22.2 (42.
São Leopoldo 7 2.64 (1.30–11.41) 19.4 (40.
Bagé 6 4.12 (1.30–11.41) 16.7 (37.
Total 10 2.88 (1.30–11.41) 20.1 (35.
1 Number of medicines included in the analysis of the MPR.
2 MPR median price ratios (= median prices / IRP)! IRP international reference pric
Sample of six cities from the Rio Grande do Sul state, Brazil, 2008-9.In private sector pharmacies, generics were the most
likely medicines to be available, followed by originator
brands and similar medicines. Because reimbursement
of medicines is very rare in Brazil, private pharmacies
typically try to offer all types of medicines, so that con-
sumers from all social classes are able to obtain their
medicines.
In the recent past (beginning of the generic’s imple-
mentation in Brazil), generics accounted for only a small
proportion of the medicines market in Brazil [30], be-
cause people were more likely to buy either the cheapest
medicine (usually a similar, at that time) or the origin-
ator brand based on the belief that the latter were of bet-
ter quality than generics or similar medicines. In recent
years, the market share of generics has increased signifi-
cantly both in absolute terms and in comparison with
originator brands and similar medicines [31]. Because of
the increased number of generics in the market and the
change in the similar’s regulation about quality tests and
product registration, we can find similars which are
cheaper or more expensive than generics, depending on
the manufacturer and whether or not they were already
adjusted to the new regulation.
Mean availability of generics in the private sector was
73.8%, a figure comparable to those observed in the
Americas, Eastern Mediterranean, Europe and Southeast
Asia and higher than those in Africa or Western Pacific,
whereas mean availability of originator brands (64.8%)
was similar to that found in upper middle income coun-
tries (61.8%) [17]. Private sector MPRs were lowest for
the similar medicines, a finding consistent with previous
research [16].
Availability of medicines in the public sector was at or
above 69% in all cities, and was slightly lower than availabil-
ity investigated in another study [32]. Placing our availabil-
ity findings in an international context we find that
availability in Brazil is lower than that of Sudan (82%) [33],
but higher than that in Malaysia (5-40%, depending on the
medicine) [34], India (0-30%, depending on the region of
the country) [35] and Chinese rural areas (38.9%) [36].ispensed by the Popular Pharmacy (n =4 facilities)
Lowest-priced similar
ility n Price Availability
(SD) MPR (Min—Max) Mean % (SD)
2) 25 2.61 (0.33–15.17) 69.4 (46.7)
2) 25 2.61 (0.33–15.17) 69.4 (46.7)
1) 28 2.86 (0.33–15.17) 77.8 (42.2)
8) 29 2.61 (0.33–15.17) 80.6 (40.1)
8) 31 2.64 (0.33–15.17) 74.3 (38.0)
es (MSH, 2007).
Table 3 Mean availability (%) of medicines and prices in the private sector (n = 30 pharmacies)
City Originator brand Lowest-priced generic Lowest-priced similar
n1 MPR2 (min—max) Availability (SD)3 n MPR (min—max) Availability (SD) n MPR (min—max) Availability (SD)
Porto Alegre 23 17.06 (2.70–94.58) 57.6% (37.6%) 21 9.97 (0.93–34.36) 63.3% (28.6%) 18 15.61 (3.17–37.87) 54.4% (33.1%)
Santa Cruz do Sul 18 25.99 (2.60–87.57) 57.6% (30.1%) 11 9.88 (0.85–37.76) 68.8% (22.8%) 23 18.34 (1.88–32.49) 39.2% (32.8%)
Caxias do Sul 17 30.63 (2.70–94.68) 58.0% (23.3%) 25 11.33 (0.93–48.92) 71.2% (25.6%) 14 12.40 (1.86–37.48) 47.2% (30.4%)
São Leopoldo 15 29.40 (4.90–66.45) 48.4% (28.3%) 17 8.42 (0.85–33.93) 65.6% (26.3%) 17 8.18 (2.75–38.82) 52.0% (31.6%)
Pelotas 35 19.08 (2.70–107.47) 75.6% (26.9%) 34 9.76 (0.87–48.95) 85.6% (25.3%) 10 9.36 (2.94–22.37) 41.2% (27.5%)
Bagé 46 16.73 (1.32–162.53) 91.0% (15.7%) 39 9.55 (0.36–49.82) 88.4% (20.6%) 20 8.81 (1.26–36.45) 54.8% (33.3%)
All 49 18.66 (1.36–168.41) 64.8% (22.8%) 42 11.32 (0.84–54.94) 73.8% (18.8%) 45 8.60 (1.11–38.84) 48.1% (26.8%)
1 N = Total number of medicines included in the analysis. To calculate the MPR, we only included medicines which were available on at least four facilities.
2 MPR median price ratios (= median prices / IRP)! IRP international reference prices (MSH, 2007).
3 Mean avalability % (standard deviation).
Sample of six cities from the Rio Grande do Sul state, Brazil, 2008-9.
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that all Brazilian citizens should have access to all essen-
tial medicines free of charge, a right which is constitu-
tionally protected [37]. The lack of several medicines in
the public sector forces patients to purchase their medi-
cines out-of-pocket in private sector outlets and may
lead to catastrophic health expenses [38] and/or under-
treatment [3].
Our affordability findings varied by therapeutic class
and type of medicine and are attributable to poor avail-
ability in the public sector. Although the lowest-paid un-
skilled government worker salary was used as a measure
of affordability it is likely that a significant part of the
population earns less [17]. This is a limitation, consider-
ing that this method cannot capture the wage for the
average worker. However, the WHO/HAI method to
evaluate affordability has the advantage of being easily
applicable and, consequently, used in many places%
Similar Ge
Figure 1 Median price differences for matched pairs of medicines. Me
to originator brand medicines in the private sector for matched pairs of m
Rio Grande do Sul state, Brazil, 2008–9.around the world allowing international comparisons. In
order to deal with this limitation, other measures have
been applied, e.g., using an impoverishment method as a
metric of affordability. Using this approach, purchases
can be estimated by determining pre- and post-payment
incomes [39]. In Brazil, 32.8% of the population live
below the poverty line of US$1 per day [25]. For these
people, any out-of-pocket expense related to medicines
could be catastrophic.
Availability of generic medicines in the public sector was
9–23% in all cities studied, whilst availability of similar
medicines was 56 – 70%. These are comparable to those
in other regions of the country, where similar medicines
are more widely available (86.4%) than generics (25%) [16].
The different levels of availability observed in each city
may partly reflect two trends; first, decentralization of
the Brazilian public health system, whereby municipal-
ities fund a proportion of medicines directly out of their0
Porto Alegre







dian price difference (%) of generic and similar medicines in relation
edicines available on at least one facility. Sample of six cities from the
0 2 4 6 8 10 12 14
Salbutamol 100mcg/dose Inhaler* (200 doses /
30 days)
Ranitidine 150mg tab (2 tab / day / 30days)
Glibenclamide 5mg tab (2 tab / day / 30days)
Ciprofloxacin 500mg tab (2 tab / day / 7days)
Amoxicilin 500mg tab (3 tab / day / 7days)
Number of days’ wages
Originatorbranded Generic Similar
Figure 2 Affordability of selected medicines. Affordability of generic, originator brand and similar medicines using a list of selected medicines.
Sample of six cities from the Rio Grande do Sul state, Brazil, 2008–9. * Generic medicines of the salbutamol 0.1 mg/dose inhaler were not
available at the time of data collection.
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tion, where supply of public sector facilities is often
problematic (inadequate quantities, problems with fre-
quency and time of distribution, and inefficient stock
control, among others) [32,40].
These supply problems have been reported in some
states of Brazil. A study carried in Minas Gerais state
indicated that in 53% of the distribution centers studied,
there was disagreement between physical count and cor-
responding records. In addition, 17% of the municipal-
ities were not working based on a list of essential
medicines [41]. Another study detected the lack of
standard operational procedures to medicine’s stock, no
access restrictions to non-authorized personnel, lack of
training to those working in the medicine’s stock and
lack of technical criteria to select the medicines to be
available to the population [42]. Also in Rio Grande do
Sul state, a study including 20 municipalities detected
problems as: (a) absence of the pharmacist in 75% of the
sample; (b) 22% of the essential items of good storage
practices were not met; (c) 10% of the municipalities did
not have stock control procedures [43].
Aware of these problems, the Department of Pharma-
ceutical Care of the Brazilian Ministry of Health has
started to propose alternatives to improve the situation.
In partnership with Brazilian universities, it has been
offering courses to pharmacists working in public health
services. It has also developed a software to manage the
pharmaceutical care in the public health system. The
tool allows inventory control, traceability of drugs dis-
tributed and dispensed, a profile of consumption and
monitoring of medication use, among other features
[44].The availability of medicines which are part of the list
of the “popular pharmacies” was high (>90% in all cities).
Similar results have been described in other regions of
the country [45]. As in public sector facilities, similar
medicines are also more frequently available than gener-
ics in “popular pharmacies”. Retail prices in “popular
pharmacies” are standardized, and, therefore, differences
observed across cities reflect the fact that different medi-
cines were available in each facility, thus resulting in a
different mean value. “Popular pharmacies”, in theory,
may represent an important additional source of access
to medicines for the population, given that prices are
much lower than those observed in private pharmacies.
Yet, the number of “popular pharmacies” is low and the
list of medicines provided is limited. The fact that a high
proportion of the users of the programme are also SUS
users – 39.2% according to a recent study [46] - suggests
that the lack of medicines in the public system is a real-
ity, and patients often need to use “popular pharmacies”
in order to obtain essential medicines, which should be
supplied free by the government.
The highest median price difference between originator
brand and the lowest-priced generic was 60%. Between
2000 to 2004, when generic medicines were launched in
Brazil, the mean price difference between generics and
originator brand products was 40% but this tended to in-
crease over time [47]. Both types of medicines presented
absolute increases in their prices, but the increase in the
price of the originator brand was relatively higher than
that of the generic equivalent(s) [47].
The government department which regulates the mar-
ket and establishes the criteria for medicine price adjust-
ments is the Câmara de Regulação do Mercado de
Bertoldi et al. Globalization and Health 2012, 8:6 Page 8 of 10
http://www.globalizationandhealth.com/content/8/1/6Medicamentos (CMED). The objective of this depart-
ment is to encourage the availability of medicines and
competition in the sector [48]. The current regulation
defines the criteria for the annual readjustment of prices
defined by the level of market competition based on the
market share of generics. The regulation also establishes
that the manufacturers of medicines may readjust the
price of their products following an index fixed in three
different bands. In order to adjust prices, manufacturers
are required to submit a report on market activity to
CMED. Only phytotherapic, homeopathic and other
medicines which can be sold with no control of prices are
not subject to the model of the top price adjustment [49].
CMED also establishes that in any sale carried out by
medicine manufacturers or wholesalers targeted to the
public or private sectors, there is a ceiling on the manufac-
turer price. In addition there is a maximum sale price to
the government. In this case, a percentage of the price
should be discounted from the manufacturer’s price in
sales targeted to the government. There is also a ma-
ximum sale price in pharmacies and drugstores for consu-
mers. These prices include taxes [18].
According to the Agência Nacional de Vigilância
Sanitária (ANVISA), which plays the role of executive
secretary for CMED, after the launch of CMED, medi-
cines costs started to decrease and actions for the regu-
lation of prices interrupted the increase trend for the
costs of these products in the country. Despite this fact,
prices in Brazil could be less expensive if taxes were
lower. On average, 36% of the price paid for medicines
in the country goes to the government due to taxes
along the supply chain. One of the main problems for
the pharmaceutical sector is the tax called Imposto sobre
Circulação de Mercadorias e Serviços (ICMS), which is
the responsibility of each state and is part of the max-
imum sale price to the consumer. The values paid by the
pharmaceutical sector to the ICMS tax reach 18%, while
the values paid for cars and food, for example, do not
exceed 12% and 8%, respectively [18].
An analysis of different types of medicines suggests
low availability of antidepressants, anti-epileptics and
anxiolytics in the public system. This could be explained
by the way these medicines are dispensed. Because their
dispensing is tightly regulated, they are available in spe-
cific facilities in some cities. If we consider only the facil-
ities which are able to distribute these medicines,
availability ranges from 75 to 100%.
Caution should be exercised when extrapolating our
data to the national level because there may be regional
differences in public and private sector availability of
medicines across the different regions of the country.
Such differences may reflect different priorities in health
care given the different profiles of morbidity outside the
study region. Still, our results compare well with otherstudies conducted in Brazil. There may be differences in
prices between this region and other regions in the
country, partly because of differences in sales taxes, but
these are marginal and are unlikely to affect our compar-
isons with other national-level evidence. Because the
proportion of informal work varies considerably across
regions of the country, care should be exercised when
extrapolating our affordability findings to the national
level.
Finally, there are inherent limitations relating to the
WHO/HAI methodology. One of them refers to the avail-
ability measure, considering that it is not related to stock
levels and might not indicate average availability. However,
the data provide an estimate of the overall situation of a
given place. This and other limitations of the WHO/HAI
methodology have been discussed elsewhere [17].
Conclusions
High prices, poor availability in public sector facilities and
low affordability suggest a number of policy implications
for the Brazilian government. First, it needs to maintain
its commitment of providing a list of essential medicines
free of charge at public facilities, aiming to fulfill the target
of 100% availability for this list of medicines. Second, the
participation of generic products in the market needs to
be increased and their prices reduced further, through bet-
ter tendering processes, so that generics become cheaper
than similar products. Although generics and similar med-
icines are alternatives to originator brands, they are also
8.6 - 11.3 more expensive than international reference
prices. Therefore, an overall reduction in medicine prices
should be a key priority. In order to achieve this, reduc-
tions in taxes and duties on medicines, and margin regula-
tions in the supply chain could be considered. Policy
measures used in developed country settings and evidence
on their performance could be used in the Brazilian con-
text [14]. Third, the routines of acquisition, stock and dis-
tribution of medicines in the public sector need to be re-
evaluated, ensuring adequate and timely distribution of
essential medicines. The use of information and commu-
nication technologies should be prioritized. Fourth, the
expansion of the list of medicines regulated by the
government is one approach to include all medicines pro-
vided by SUS. This expansion would lead to the purchase
of medicines at lower prices by the government. Fifth, if
the government continues to be unable to provide for free
all essential medicines needed by the population, it is ne-
cessary to expand the popular pharmacy programme, by
increasing the number of facilities and the number of
medicines available. Alongside that, the quantity and qual-
ity of information available to patients about prices should
also improve. Finally, the private market requires tighter
regulation, so that only OTC medicines are dispensed
without a prescription.
Bertoldi et al. Globalization and Health 2012, 8:6 Page 9 of 10
http://www.globalizationandhealth.com/content/8/1/6Endnotes
aKey medicines are those suitable and used for inter-
national comparisons (global and regional list) or com-
monly used therapeutic alternatives to those which are
part of the global and regional list. bOrdinary people are
defined as the lowest-paid unskilled government worker.
cAll collected data (price and availability) were entered
in the workbook, consolidated and summarized. Data
were entered twice in order to avoid entry errors. Based
on the unique feature of the Brazilian medicines market,
comprising originators, generics and similar medicines,
three workbooks were analyzed: originator brands vs.
generics, originator brands vs. similar medicines, and
generics vs. similar medicines.
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